Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Operating Leases (2021 - 2025)

Historic Operating Leases for Vivos Therapeutics (VVOS) over the last 5 years, with Q3 2025 value amounting to $2.9 million.

  • Vivos Therapeutics' Operating Leases rose 14749.57% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 million, marking a year-over-year increase of 14749.57%. This contributed to the annual value of $1.0 million for FY2024, which is 3195.27% down from last year.
  • As of Q3 2025, Vivos Therapeutics' Operating Leases stood at $2.9 million, which was up 14749.57% from $2.8 million recorded in Q2 2025.
  • Over the past 5 years, Vivos Therapeutics' Operating Leases peaked at $2.9 million during Q2 2022, and registered a low of $641000.0 during Q4 2021.
  • Over the past 5 years, Vivos Therapeutics' median Operating Leases value was $1.9 million (recorded in 2022), while the average stood at $1.9 million.
  • Its Operating Leases has fluctuated over the past 5 years, first skyrocketed by 21107.64% in 2022, then plummeted by 5047.82% in 2025.
  • Quarter analysis of 5 years shows Vivos Therapeutics' Operating Leases stood at $641000.0 in 2021, then soared by 211.08% to $2.0 million in 2022, then fell by 23.72% to $1.5 million in 2023, then crashed by 31.95% to $1.0 million in 2024, then skyrocketed by 176.91% to $2.9 million in 2025.
  • Its last three reported values are $2.9 million in Q3 2025, $2.8 million for Q2 2025, and $932000.0 during Q1 2025.